Compare MOGO & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOGO | RLYB |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 24.1M |
| IPO Year | N/A | 2021 |
| Metric | MOGO | RLYB |
|---|---|---|
| Price | $1.30 | $0.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 145.9K | ★ 229.6K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $29,215,516.00 | $674,000.00 |
| Revenue This Year | $61.97 | N/A |
| Revenue Next Year | $6.28 | N/A |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $0.74 | $0.22 |
| 52 Week High | $3.83 | $1.24 |
| Indicator | MOGO | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 55.02 |
| Support Level | $1.11 | $0.59 |
| Resistance Level | $1.26 | $0.68 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 64.52 | 46.34 |
Mogo Inc is a Canadian-based financial technology company. It offers a finance application to consumers with solutions that help them to control their financial health. At Mogo, users can sign up for a free account and get access to products and solutions that help users to monitor their credit score, protect themselves from identity fraud, control their spending, and borrow responsibly. Company offers digital loans and mortgages and also offer a digital payments platform that powers next-generation card programs for both established world-wide corporations and fintech companies in Europe and Canada.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.